Table 1.
Baseline Clinical and Demographic Characteristics of Study Population
| Transgender women (N = 26) | Transgender men (N = 24) | p | |
|---|---|---|---|
| Age | 19.9 ± 2.5 | 20.3 ± 2.3 | .551 |
| Weight (kg) | 69.1 ± 11.9 | 68.5 ± 21.4 | .893 |
| CrCl (mL/min) | 136.2 ± 34.4 | 116.9 ± 48.4 | .108 |
| Race/ethnicitya | |||
| White | 19 (73.1%) | 20 (83.3%) | .462 |
| Black | 4 (15.4%) | 2 (8.3%) | |
| Asian | 0 (0%) | 2 (8.3%) | |
| Hispanic | 9 (39.1%) | 2 (8.7%) | |
| Other | 1 (3.9%) | 2 (8.3%) | |
| Route of estradiol administration | |||
| Oral/sublingual | 14 (53.9%) | — | |
| Intramuscular | 12 (46.2%) | ||
| Route of testosterone administration | |||
| Subcutaneous | — | 12 (50%) | |
| Intramuscular | 12 (50%) | ||
| Spironolactone useb | 18 (69.2%) | — | |
All values presented as mean ± SD or n (%).
a
Participants may have self-reported as multiple races or ethnicities.
b
There were eight transgender women receiving progesterone, one receiving finasteride, and one receiving leuprolide as part of their gender affirming hormone therapy.
CrCl, Creatinine clearance.